These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31943747)

  • 1. Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis.
    Megaly M; Glogoza M; Xenogiannis I; Vemmou E; Nikolakopoulos I; Willson L; Monyak DJ; Sullivan P; Stanberry L; Sorajja P; Chavez I; Mooney M; Traverse J; Wang Y; Garcia S; Poulose A; Burke MN; Brilakis ES
    Catheter Cardiovasc Interv; 2021 Jan; 97(1):32-38. PubMed ID: 31943747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes With Combined Laser Atherectomy and Intravascular Brachytherapy in Recurrent Drug-Eluting Stent In-Stent Restenosis.
    Megaly M; Glogoza M; Xenogiannis I; Vemmou E; Nikolakopoulos I; Omer M; Willson L; Monyak DJ; Sullivan P; Stanberry L; Chavez I; Mooney M; Traverse J; Wang Y; Garcia S; Poulose A; Burke MN; Brilakis ES
    Cardiovasc Revasc Med; 2021 Jan; 22():29-33. PubMed ID: 32571761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracoronary Brachytherapy for Recurrent Drug-Eluting Stent Failure.
    Negi SI; Torguson R; Gai J; Kiramijyan S; Koifman E; Chan R; Randolph P; Pichard A; Satler LF; Waksman R
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1259-1265. PubMed ID: 27339842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular brachytherapy versus drug-eluting stents in the treatment of in-stent restenosis: A meta-analysis of long-term outcomes.
    Benjo A; Cardoso RN; Collins T; Garcia D; Macedo FY; El-Hayek G; Nadkarni G; Aziz E; Jenkins JS
    Catheter Cardiovasc Interv; 2016 Feb; 87(2):200-8. PubMed ID: 25963829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary Intravascular Brachytherapy for Recurrent Coronary Drug-Eluting Stent In-Stent Restenosis: A Systematic Review and Meta-Analysis.
    Megaly M; Glogoza M; Xenogiannis I; Vemmou E; Nikolakopoulos I; Omer M; Saad M; Willson L; Monyak DJ; Sullivan P; Pershad A; Chavez I; Mooney M; Traverse J; Wang Y; Garcia S; Poulose A; Burke MN; Brilakis ES
    Cardiovasc Revasc Med; 2021 Feb; 23():28-35. PubMed ID: 32883584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
    Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
    Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Northwell intracoronary brachytherapy for the treatment of recurrent drug eluting stent in-stent restenosis (NITDI study group).
    Meraj PM; Patel K; Patel A; Doshi R; Srinivas G; Jauhar R; Kaplan B; Garzon R; Sharma A; Cao Y; Diaz Molina F; Sharma R
    Catheter Cardiovasc Interv; 2021 Jan; 97(1):41-46. PubMed ID: 31930652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy.
    Yerasi C; Chen Y; Case BC; Forrestal BJ; Shea C; Zhang C; Torguson R; Ben-Dor I; Satler LF; Waksman R
    Am J Cardiol; 2021 Mar; 142():44-51. PubMed ID: 33285089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial.
    Alli OO; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA; Holmes DR;
    Am Heart J; 2012 Mar; 163(3):438-45. PubMed ID: 22424015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
    Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
    JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Vascular Brachytherapy and Stenting for the Treatment of In-Stent Restenosis.
    Chen Y; Buchanan KD; Chan RC; Zhang C; Torguson R; Satler LF; Waksman R
    Am J Cardiol; 2020 Mar; 125(5):712-719. PubMed ID: 31889523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular brachytherapy for patients with drug-eluting stent restenosis.
    Bonello L; Kaneshige K; De Labriolle A; Roy P; Lemesle G; Torguson R; Satler LF; Pichard AD; Lindsay J; Waksman R
    J Interv Cardiol; 2008 Dec; 21(6):528-34. PubMed ID: 18973502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis.
    Rhee TM; Lee JM; Shin ES; Hwang D; Park J; Jeon KH; Kim HL; Yang HM; Han JK; Park KW; Hahn JY; Koo BK; Kim SH; Kim HS
    JACC Cardiovasc Interv; 2018 May; 11(10):969-978. PubMed ID: 29798774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus-eluting stent implantation and beta-irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound.
    Schiele TM; König A; Rieber J; Erhard I; Leibig M; Theisen K; Siebert U; Klauss V
    Am Heart J; 2005 Aug; 150(2):351-7. PubMed ID: 16086942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in-depth review of retrospective studies to assess the role of vascular brachytherapy for the treatment of complex patients with multiple risk factors for DES-ISR.
    Mittal A; Dhaliwal SS; Bhullar D; Dass J
    Rev Cardiovasc Med; 2022 Feb; 23(2):54. PubMed ID: 35229545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intravascular ultrasound analysis of the mechanisms of restenosis comparing drug-eluting stents with brachytherapy.
    Kim SW; Mintz GS; Escolar E; Ohlmann P; Pregowski J; Tyczynski P; Hassani SE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R; Weissman NJ
    Am J Cardiol; 2006 May; 97(9):1292-8. PubMed ID: 16635598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.